New agreement for Airsonett with the region of Halland in Sweden for treatment of severe, uncontrolled allergic asthma and difficult-to-treat atopic eczema with TLA via public healthcare

Airsonett AB announced today that the company had signed an agreement with the region of Halland in Sweden. The agreement is for the treatment of patients with severe, uncontrolled allergic asthma and difficult-to-treat atopic eczema with the company’s patented technology Temperature-controlled Laminar Airflow (TLA). The technology gives patients particle- and allergen-free air when they rest or sleep.

The region of Halland is the fifth region in Sweden to sign an agreement with Airsonett. The company has already signed agreements with the regions of Stockholm, Östra Götaland, Västra Götaland and Kalmar. The region of Halland is, together with the regions of Skåne and Stockholm, one of the leading regions in Sweden when it comes to professional allergy treatment. (Allergia, September 2019)

"We are very pleased that the region of Halland also signs an agreement with Airsonett for treatment with TLA. More patients with severe, uncontrolled allergic asthma and difficult-to-treat atopic eczema will now have access to treatment, which can greatly improve their quality of life. We have also seen that the treatment can lower the costs for the public healthcare, due to the good treatment results, reduced costs for drug treatment and fewer emergency visits", says Anders Due-Boje, CEO Airsonett AB.

TLA Treatment for severe, uncontrolled asthma is part of the national guidelines for asthma treatment since 2015, and it is today prescribed to many patients in Sweden with excellent results. The treatment takes place in the home with the Airsonett Air4, a patented medical device, and is well-suited for both children and adults.

For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu

About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed, and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.